Compare RCMT & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | SIGA |
|---|---|---|
| Founded | 1971 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.1M | 223.8M |
| IPO Year | 1997 | 2016 |
| Metric | RCMT | SIGA |
|---|---|---|
| Price | $34.70 | $2.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | 27.5K | ★ 780.9K |
| Earning Date | 04-03-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ 27.38 | N/A |
| EPS | ★ 1.20 | 0.13 |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $12.46 | $224.81 |
| P/E Ratio | $55.62 | ★ $22.15 |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $2.83 |
| 52 Week High | $32.50 | $9.45 |
| Indicator | RCMT | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 82.90 | 34.55 |
| Support Level | $27.02 | N/A |
| Resistance Level | N/A | $4.84 |
| Average True Range (ATR) | 1.03 | 0.14 |
| MACD | 0.37 | -0.00 |
| Stochastic Oscillator | 94.46 | 24.17 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.